ONC 206
Spinal Cord Glioma
Sabine Mueller, MD, PhDSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Spinal Cord Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Meyer Children's Hospital IRCCS | Phase 2 | NR |
Same molecule, other indications
ONC 206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →